The discovery of hypercalcemic diseases due to loss-of-function mutations in 25-hydroxyvitamin D-24-hydroxylase has placed a new demand for sensitive and precise assays for 24, 
S erum 25-hydroxyvitamin D (25-OH-D) is widely ac-
cepted as a biomarker of vitamin D status (1) . Vitamin D plays important roles in the body including the regulation of calcium/phosphate homeostasis and the cell cycle (2) . Over the past 10 years, many epidemiological studies have demonstrated an inverse correlation between serum 25-OH-D levels and a broad range of important disease states (3, 4) , which has in turn emphasized the importance of adequate vitamin D status (5) . Currently, serum 25-OH-D is routinely measured by methods involving RIA, HPLC, or liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based technologies (6) .
Recently some of us (7) showed that loss-of-function mutations of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) in a group of German, Turkish, and Russian children are associated with the hypercalcemic condition, idiopathic infantile hypercalcemia (IIH). With this newly acquired knowledge about the importance of the catabolic enzyme CYP24A1 (8) , there has developed renewed interest in measuring its main circulating product, 24,25-dihydroxyvitamin D 3 [24,25- 2 D 3 to the plasma vitamin D binding globulin allowed for early estimates of the levels of this catabolite (9) . However, methods required precise chromatography steps to resolve 24,25-(OH) 2 D 3 from its more abundant precursor, 25-OH-D 3 and from the other dihydroxyvitamin D metabolites including 25,26-dihydroxyvitamin D 3 and 25-OH-D 3 -26,23-lactone, which are often increased in serum from hypervitaminotic D animals (10) . In patients receiving vitamin D 2 , the analytical problem of accurately assaying 24-hydroxylated vitamin D 2 and D 3 becomes even more complex and time consuming.
The emergence of LC-MS/MS as a tool to quantify a wide range of clinically important bioactive hormones and metabolites has been a major advance in clinical chemistry. Tandem mass spectrometry provides the ideal universal detector for vitamin D metabolites separated by conventional liquid chromatography techniques (11) . Its only drawback has been the identification of interfering substances such as 3-epi-25-OH-D 3 in a 25-OH-D assay (12) (13) , which make the chromatographic step particularly important.
In this paper, we describe a sample preparation and derivatization method that allows the simultaneous assay in serum in both humans and mice of all abundant metabolites of both vitamin D 2 
Materials and Methods

Human and animal studies
Serum samples were analyzed from the following: 1) 163 healthy, white, postmenopausal women who were part of a 1-year randomized prospective, placebo-controlled VIDOS (Vitamin D Supplementation in Older Subjects) clinical trial approved by the Creighton University Institutional Review Board and published previously (14) ; 2) 110 healthy older African American women who were enrolled in a randomized, double-blind vitamin D supplementation trial at Creighton Medical Center and Indiana University Medical Center published previously (15) ; and 3) 198 healthy young women (119 Caucasian and 79 African American) enrolled in a 1-year prospective, randomized, placebo controlled vitamin D supplementation trial published previously (16) . Serum samples from patients with idiopathic infantile hypercalcemia were provided by Schlingmann et al (7) as previously described. Mouse sera were provided by Dr Hector F. DeLuca and Dr René StArnaud; and all mice were managed in compliance with protocols approved by the University of Wisconsin Research Animal Resources Center or McGill University Animal Care Committee as previously described (17, 18 The synthesis of the deuterated internal standard, 24R,25-dihydroxyvitamin D 3 (26,26,26,27,27,27-d 6 ) (Figure 1) (1, seocalciferol-d 6 ) starts with inhoffen-lythgoe diol (2), which can be prepared from vitamin D 2 (19) and converted to the acetate 3 by known procedures (20) . Ketone 3 was coupled with the phosphine anion 4 in tetrahydrofuran (THF) at Ϫ78°C to afford, after desilylation with tetrabutyl-ammonium fluoride in THF and subsequent saponification with sodium methoxide in THF, the desired deuterated vitamin D 3 metabolite 1 (purity information provided in Supplemental Table 1 
Liquid chromatography and tandem mass spectrometry
LC-MS/MS analysis was performed using an Acquity UPLC connected in-line with a Xevo TQ-S mass spectrometer in electrospray positive mode (Waters). Chromatographic separations were achieved using a BEH-Phenyl UPLC column (1.7 m, 2.1 ϫ 50 mm) (Waters) and methanol/water-based gradient solvent system. The serum extract run on LC-MS/MS is the equivalent of 17 L of serum or approximately one sixth of the 100-L sample extracted and the chromatography runtime is less than 5 minutes. Further details of the chromatography, optimized mass spectrometer settings, transitions for multiple reaction monitoring, and data management are provided in Supplemental Table  2 , A and B.
Results
Optimization and performance of the simultaneous vitamin D metabolite assay
Derivatization of vitamin D metabolites with DMEQ-TAD offers the advantage of improving ionization efficiency relative to native metabolites and increasing molecular mass by 363 Da, to a region of the mass spectrum in which there is reduced background. The major characteristic ions for derivatized 25-OH-D 3 , 25-OH-D 2 , and 24,25-(OH) 2 D 3 were their molecular ions [MϩH] ϩ at a mass/charge (m/z) ratio of 746.6, 758.6 and 762.6 respectively, and when subjected to collision-induced dissociation under optimized conditions they yield an A-ring/ DMEQ-TAD fragment (m/z 468) and a DMEQ-TAD fragment (m/z 247) as the major products. The fragmentation pattern for the 24,25-(OH) 2 D 3 adduct is shown in Figure 2 , A and B. The m/z 468 was selected as the fragment ion for multiple reaction monitoring (MRM) analysis because of greater specificity and lower background as compared with the fragment at m/z 247. DMEQ-TAD adducts of the target analytes consisted of 6R and 6S isomers, of which the more abundant 6S isomer was used for quantitation. In a representative serum sample, the 6S isomers of the DMEQ- Table 3 ). Lower limits of quantification as defined by signal to noise ratios of 10 or greater were estimated to be within the 0.1-to 0.2-ng/mL range and lower limits of detection (signal to noise ratio Ն 3) were estimated to be as low as 0.04 ng/mL. Intraassay and interassay imprecision was determined by analyzing five replicates of a serum sample containing 55 nmol/L 25-OH-D 3 , 83 nmol/L 25-OH-D 2 , and 6 nmol/L of 24,25- Figure  3B and indicates that a ratio below 20 in a population corresponds to vitamin D sufficiency and a ratio above 20 suggests vitamin D insufficiency (25) . Although less than 20% of these women exhibited measurable serum 25-OH-D 2 at baseline, this metabolite was negligible (Ͻ5 nmol/L) after vitamin D 3 supplementation for 1 year. 3-epi-25-OH-D 3 was measurable in most patients and averaged 6% of the serum 25-OH-D 3 value, in agreement with data from others (26, 27) .
Utility of simultaneous vitamin D metabolite assay in patients with IIH due to loss-of-function CYP24A1 mutations
The simultaneous assay was used to measure vitamin D metabolite levels in serum samples from two patients previously diagnosed with IIH due to CYP24A1 mutations (16) ( Table 1 ). Both patients with loss-of-function mutations of CYP24A1 had virtually undetectable levels of serum 24,25-(OH) 2 D 3 . Whether these measurable traces of 24,25-(OH) 2 D 3 in IIH patients( Figure 4A ) are small amounts of the metabolite made by other cytochrome P450s or represent other interfering dihydroxyvitamin D metabolites with the same retention time and mass spectral characteristics is unknown at this time (28, 29) . Over the years, there have been reports that cytochrome P450s, other than CYP24A1, can generate 24,25-(OH) 2 D 3 , but those reports are mainly from in vitro studies (8, 28) and it is difficult to judge whether this can occur in vivo. On the other hand, if the trace metabolite is not 24,25-(OH) 2 
Utility of simultaneous vitamin D metabolite assay in patients with hypervitaminosis D
The simultaneous vitamin D metabolite assay was used to assess a patient with hypercalcemia due to an excessive intake of vitamin D 3 (30) . The 78-year-old patient pre- Figure 4D ). The ability to detect multiple metabolites simultaneously is a major advantage of the use of DMEQ-TAD (21, 22) .
Utility of simultaneous vitamin D metabolite assay in rodent serum samples
Rodent studies are often limited by the volumes of serum/plasma available for analysis and often necessitate sample pooling to allow for detection of vitamin D metabolites. The simultaneous vitamin D metabolite assay was used to analyze 100-L samples from individual mice in a metabolic study involving wild-type, CYP2R1 knockout, CYP27A1 knockout, and CYP2R1/CYP27A1 double-knockout mice (17) ( Table 2 (7, 30) . Taken together, the simultaneous assay of 25-OH-D 3 and 24,25-(OH) 2 D 3 is a valuable screening tool for patients presenting with hypercalcemia.
We show here the utility of the new method for the analysis of vitamin D metabolites including 24,25-(OH) 2 D 3 in rodent sera (17, 18) . The example involving mouse sera shows that LC-MS/MS, unlike certain commercially available RIAs (32), is not sensitive to the presence of blood proteins from certain species. Also unlike commercially available RIAs, LC-MS/MS can resolve or remove the complications caused by the presence of high levels of 24,25-(OH) 2 D 3 and 25-OH-D 3 -26,23-lactone found in serum from wild-type mice (9) . The rodent studies using CYP24A1 reinforce the current dogma that this cytochrome P450 is responsible for the production of many side-chain hydroxylated metabolites including 24,25-(OH) 2 D 3 and 25-OH-D 3 -26,23-lactone (7) . The examples here show that in addition to the advantage the LC-MS/MS method measures multiple vitamin D metabolites, it is sensitive enough to allow convenient analyses on individual animals as opposed to pooled samples. Animal-to-animal variability in mice with a similar genotype and diet is small and allows for more rigorous statistical analysis.
LC-MS/MS methodology continues to improve in terms of sensitivity, and the addition of a derivatization step with DMEQ-TAD improves this by at least 10-fold over conventional LC-MS/MS using the native vitamin D metabolites. LC-MS/MS methods, including the current simultaneous assay, have proven to be superior to immunoassays in their detection and accurate measurement of 25-OH-D 2 that is present at high concentrations in vitamin D 2 -treated patients (33, 34) . Part of the utility of the LC-MS/MS method for 24,25-(OH) 2 D 3 is that it uses much smaller aliquots of serum than competitive-binding assays that preceded it. In addition, because there are a variety of Cookson reagents/dienophiles now becoming available (35, 36) , we can expect this technology to become even more sensitive in the years to come and these improvements will eventually allow for the routine inclusion of 1,25-(OH) 2 D 3 in the metabolites that can be measured using a 100-L serum aliquot.
